DelveInsight

The estimated total number of incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the US is expected to reach 713,294 by 2025 as per the latest report of DelveInsight.

Prevalent cases of PAH in the 7MM (US, Germany, Spain, Italy, France, United Kingdom and Japan) are around 70,000 in 2016, out of which females are the ones to be majorly affected with this disease, accounting for 70% of the prevalent cases.

Long shot once but now engaging giant pharmaceutical companies

Cutaneous T-Cell Lymphoma market size in 7MM's is estimated to increase at a CAGR of 1.6% for the forecasted period (2013-2025), as per the latest report of DelveInsight.

Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) is the most talked about immuno-oncology target. Programmed Death 1 (PD-1) is an immune inhibitory receptor expressed on several immune cells, particularly cytotoxic T cells.

Offering Mid-Year Discounts on Pharmaceutical Market Research Reports

Report covers ten cancer indications: Breast Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin's disease and Non-Hodgkin Lymphoma

This report provides an overview of the Alpha Antitrypsin Deficiency and global market size of the Alpha Antitrypsin Deficiency for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan.

DelveInsight's report, "PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, "gives the comprehensive insights on the PD-1 and PD-L1 Inhibitors.

DelveInsight Report, "Natural Killer Cells Therapies- Competitive Landscape, Technology and Pipeline Analysis, emphasizes on the currently active NK cell products in research and development.